Follow this preprint
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
View ORCID ProfileShadisadat Esmaeili, View ORCID ProfileKatherine Owens, Jessica Wagoner, View ORCID ProfileStephen J. Polyak, Judith M. White, View ORCID ProfileJoshua T. Schiffer
doi: https://doi.org/10.1101/2023.08.23.23294505
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Shadisadat Esmaeili
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Katherine Owens
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Jessica Wagoner
2Department of Medicine, University of Washington; Seattle, WA, USA
Stephen J. Polyak
2Department of Medicine, University of Washington; Seattle, WA, USA
Judith M. White
3Department of Cell Biology, University of Virginia; Charlottesville, VA, USA
Joshua T. Schiffer
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
2Department of Medicine, University of Washington; Seattle, WA, USA

Data availability
The data analyzed in this work was previously published by Hay et al. and Schilling et al. and is available on github at
https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0
Pharmacodynamics data is available on guithub at https://github.com/sEsmaeili/Covid_Rebound
Posted April 17, 2024.
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, Stephen J. Polyak, Judith M. White, Joshua T. Schiffer
medRxiv 2023.08.23.23294505; doi: https://doi.org/10.1101/2023.08.23.23294505
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (218)
- Cardiovascular Medicine (3228)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13241)
- Forensic Medicine (19)
- Gastroenterology (889)
- Genetic and Genomic Medicine (5059)
- Geriatric Medicine (470)
- Health Economics (772)
- Health Informatics (3181)
- Health Policy (1128)
- Hematology (423)
- HIV/AIDS (1003)
- Medical Education (468)
- Medical Ethics (125)
- Nephrology (513)
- Neurology (4804)
- Nursing (254)
- Nutrition (715)
- Oncology (2475)
- Ophthalmology (701)
- Orthopedics (278)
- Otolaryngology (337)
- Pain Medicine (320)
- Palliative Medicine (89)
- Pathology (528)
- Pediatrics (1277)
- Primary Care Research (550)
- Public and Global Health (7365)
- Radiology and Imaging (1668)
- Respiratory Medicine (969)
- Rheumatology (473)
- Sports Medicine (413)
- Surgery (534)
- Toxicology (69)
- Transplantation (232)
- Urology (199)